CONMED Corporation Reports Q1 2026 Financial Results with Increased Net Income

CONMED Corporation reported its financial results for the first quarter of 2026, revealing a net income of $13.8 million, or $0.45 per diluted share, compared to $6.0 million, or $0.19 per diluted share, in the same period last year. The company’s net sales for the quarter totaled $317.0 million, a slight decrease of 1.3% from $321.3 million in the first quarter of 2025. This decline was attributed primarily to the exit from several products in the gastroenterology product line, which saw sales drop from $25.0 million to $9.5 million year-over-year. However, sales in orthopedic surgery increased by 6.8%, driven by growth in procedure-specific and BioBrace® product offerings.

The company’s gross profit margin improved to 57.9% from 55.3% in the prior year, largely due to a $1.9 million benefit from the termination of a distribution agreement with W.L. Gore & Associates, Inc. Additionally, CONMED's cost of sales decreased to $133.6 million from $143.5 million, reflecting operational efficiencies and favorable product mix. Selling and administrative expenses also fell to $141.7 million from $148.8 million, aided by a reduction in stock-based compensation costs and a gain from the sale of certain gastroenterology assets.

In terms of operational metrics, CONMED's total assets decreased slightly to $2.31 billion as of March 31, 2026, from $2.33 billion at the end of 2025. The company reported a current ratio of 2.29, indicating a solid liquidity position. Cash and cash equivalents stood at $35.0 million, down from $40.8 million at the end of the previous year. The company’s long-term debt increased to $860.2 million from $834.2 million, reflecting ongoing investments and financing activities.

Strategically, CONMED has been optimizing its product portfolio, including the recent decision to exit the gastroenterology market, which is expected to streamline operations and focus resources on higher-growth areas. The company also engaged a consulting firm to enhance its manufacturing operations amid rising costs and supply chain challenges. Looking ahead, CONMED anticipates continued growth in its orthopedic surgery segment and is focused on maintaining operational efficiencies while navigating the complexities of the current economic environment.

Overall, CONMED's first-quarter results reflect a combination of strategic repositioning and operational improvements, setting a foundation for future growth despite the challenges posed by market conditions and product line adjustments. The company remains committed to leveraging its strengths in surgical devices and equipment to drive long-term value for shareholders.